Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EMN 2018 | CAR T-cells for mulitple myeloma

Fabio Malavasi • 19 Apr 2018
EMN 2018
Multiple Myeloma CAR-T

In this video, Fabio Malavasi, MD, of the University of Turin, Turin, Italy, discusses immunotherapy in multiple myeloma (MM) from the 1st European Myeloma Network Meeting (EMN) 2018, in Turin, Italy. Prof. Malavasi highlights the innovative apporach of CAR T-cells, before mentioning the current limitations preventing the further development and application of this treatment.

More from Fabio Malavasi

3:40
Kinase inhibitor advances in MM: predictive biomarkers & efficacy of daratumumab
Fabio Malavasi • 19 Apr 2018
3:29
New abstracts outline how MM cleverly evades immune detection
Fabio Malavasi • 19 Apr 2018

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals